Syntis Bio, Inc.
PrivateLast Round
Series A
Jul 1, 2025
Est. Valuation
$67M
Total Funding Raised
$53.5M
Company Overview
Syntis Bio, Inc. operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series A round in July 2025.
Syntis Bio, Inc. is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine's biology for conditions like obesity, diabetes, and rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Syntis Bio, Inc. Comparables
Compare Syntis Bio, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Glyscend Therapeutics | 86% | |
| Aphaia Pharma | 76% | |
| Biolexis Therapeutics, Inc. | 75% |
For institutional investors. Book with your work email.
Syntis Bio, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 1, 2025 | ||||
| Grant | Jul 1, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Syntis Bio, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| Cerity Partners Ventures | Series A, Seed |
| Cerberus Ventures | Series A |
| Mansueto Office | Series A |
| Woori Venture Partners Co., Ltd. | Series A |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| Colorcon Ventures | Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 11, 2026
David Rosenbaum appointed as Chief Development Officer.
- Mar 3, 2026
Christo Shalish appointed as the new Chief Business Officer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 23, 2026
Syntis Bio, Inc. plans to start a phase 2 study of SYNT-101 in 2027, an oral non-incretin weight-loss therapy that it hopes can serve as a standalone treatment or combine with existing medicines.
- is_developingSep 2, 2026
Syntis Bio, Inc. is developing pill-based therapies that harness the small intestine's unique biology to transform oral therapy for obesity, diabetes and rare diseases, with the work still at an early stage.
For institutional investors. Book with your work email.
Syntis Bio, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Syntis Bio, Inc.'s valuation, stock price, and market status.
Is Syntis Bio, Inc. a public or private company?
Syntis Bio, Inc. is a private company.
What is the current stock price of Syntis Bio, Inc.?
Syntis Bio, Inc. is a private company, so its shares have no public market price. Caplight tracks Syntis Bio, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Syntis Bio, Inc. worth (valuation)?
Syntis Bio, Inc.'s valuation is estimated at $67.0M based on funding round data.
Can I buy Syntis Bio, Inc. stock?
Syntis Bio, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Syntis Bio, Inc.'s last funding round?
Syntis Bio, Inc.'s most recent funding round was Series A on July 1, 2025.
Who are the main investors in Syntis Bio, Inc.?
Key investors in Syntis Bio, Inc. include Cerberus Ventures, Cerberus Capital Management.
Will Syntis Bio, Inc. IPO soon?
No public IPO plans have been announced for Syntis Bio, Inc..
How can I track Syntis Bio, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Syntis Bio, Inc.'s shares on secondary markets.